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Clinical trials of CTLA-4 and PD-1/PD-L1 antibodies
(Ab) have shown responses limited to 10-30% of
patients. Increasing evidence suggests radiation (RT) can
enhance responses to checkpoint therapies. However,
understanding of tumor-derived factors that influence
response is limited, and many preclinical models are
designed to be immunogenic. We sought to develop a
model of immunologic heterogeneity to study factors
that influence responses to RT and immunotherapy.
Two tumor clones Py117 and Py8119 derived from the
PyMT mammary carcinoma in C57Bl/6 mice engraft
efficiently and upon RT the Py117 but not Py8119
tumors regressed. There was no significant difference
detected in radiosenstivity by clonogenic survival,
hypoxia by pimonidazole staining, or angiogenesis
through Meca32 staining. Tumor dissociation 10 days
after 12 Gy treatment revealed a significant increase in
CD45+ leukocytes, CD8+ T cells and decreased CD4+
T cells, myeloid derived suppressor cells, and macro-
phages in Py117 tumors but minimal changes in Py8119
tumors. Secondly, there was elevated MHCI and
induced PD-L1 expression in Py117 compared to
Py8119 tumors suggesting a greater response may be
obtained with immunotherapy. Mice treated with 12 Gy,
12Gy + PD-1 Ab, and a single dose of CTLA-4 Ab 3
days prior to RT and PD-1 therapy revealed prolonged
response with RT + PD-1 and RT + PD-1 + CTLA-4
groups, significant by repeated measures analysis. Nota-
bly 2/8 tumors treated with RT + PD-1 and 6/8 mice
treated with RT + PD-1 +CTLA-4 were undetectable at
day 81. Implantation of tumors with different ratios of
Py117 and Py8119 cells revealed that 50% inoculation of
Py117 cells leads to an immune response against both
tumor clones characterized by greater tumor MHCI
expression, CD8+ T cell infiltration and decreased
macrophage infiltration. We hypothesized that treating
the unresponsive Py8119 tumors with CD40 agonist
would replicate the findings of the mixing experiment.
CD40 Ab in combination with 20 Gy RT resulted in a
greater antitumor response with significant decrease in
tumor size not seen in either treatment alone. Evalua-
tion of the tumor microenvironment revealed MHCI
expression was enhanced, macrophage infiltration was
decreased and CD8+ T cells were increased. These
results support that tumor immunologic heterogeneity
can influence immune responses after radiation and tar-
geting suppressive factors in the tumor microenviron-
ment can enhance responses. This model of
heterogeneity without genetic manipulation is ideal to
study tumor-derived factors that enhance or suppress the
immune response after RT and could inform clinical
approaches to radiation and immunotherapy combinations.
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